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Strains ofNeisseria gonorrhoeaewith mosaic penA genes bearing novel point mutations in penA have been isolated from ceftri-
axone treatment failures. Such isolates exhibit significantly higher MIC values to third-generation cephalosporins. Here we re-
port the in vitro isolation of two mutants with elevated MICs to cephalosporins. The first possesses a point mutation in the
transpeptidase region of the mosaic penA gene, and the second contains an insertion mutation in pilQ.
Increases in MICs and antibiotic resistance have been observedamong clinical isolates of Neisseria gonorrhoeae and have re-
sulted in a greater incidence of treatment failure (1–6). -Lactam
resistance results collectively from mutations in four genes—penA
(7, 8), ponA (9, 10), mtrR (11–13), and the porBIb allele of the
porin gene (14, 15)—and increased cephalosporin resistance re-
quires the presence of a mosaic penA gene (16–18), a variant pre-
sumably resulting from gene transfer and recombination (19).
Mutations within the mosaic penA gene can result in still greater
resistance to cephalosporins (5, 6).
The penA and ponA genes of 11 gonococcal isolates with MICs
to penicillin and ceftriaxone ranging from 4.0 to 8.0 g/ml and
0.008 to 0.060 g/ml, respectively, were sequenced using
GenomeLab DTCS-Quickstart kits (Beckman Coulter, Brea, CA),
with product analysis performed on a CEQ3000 instrument, and
the data were analyzed using DNAStar software. Isolates with
MICs to ceftriaxone ranging from 0.008 to 0.015 g/ml demon-
strated a single additional codon that coded for the insertion of an
aspartic acid residue, while all four of the isolates with MICs rang-
ing from 0.03 to 0.06g/ml possessed mosaic penA genes. In all of
the isolates sequenced, the ponA gene contained a single point
mutation (Table 1) as described elsewhere (10). The MtrR pheno-
type of all of the isolates was established by determining their
resistance to 1.2 g/ml of erythromycin and 600 g/ml of Triton
X-100 (12). Two isolates with nonmosaic penA genes and two with
mosaic penA genes (Table 1) were chosen for further study as to
their potential to mutate to greater resistance to cephalosporins.
Gradient plates of GC base agar with Isovitalex (Becton, Dickin-
son and Company, Sparks, MD) and either 4.0 or 6.0 g/ml of
cefpodoxime in the agar substratum were seeded with 5  1010
CFU of each of the isolates to determine the range of concentra-
tions over which mutants could be selected. Mutants were ob-
tained for both of the mosaic penA strains SPL4 and SPN284 on
both concentrations of cefpodoxime. No mutants were obtained
for the two nonmosaic penA strains SPN275 and SPN280. Mu-
tants derived from SPL4 and SPN284 were tested for MICs by the
agar dilution method (20). The growth patterns observed on the
gradient plates and the MICs obtained for the mutants (Table 2)
suggested that 3.0 to 3.5 g/ml of cefpodoxime was the concen-
tration likely to be optimal for the selection of mutants. The actual
frequencies of mutation to elevated resistance to cefpodoxime
(Cpdr) were determined by seeding GC base agar containing 3.0
g/ml of cefpodoxime with approximately 2.0 109 CFU as de-
termined by viable count on plain GC base agar and were found to
be 2.1 109 Cpdr/CFU for SPL4 and 1.9 109 Cpdr/CFU for
SPN284. By comparison, the frequency of mutation to resistance
to rifampin (30g/ml) was similarly determined to be 3.0 109
Rifr/CFU for both SPN284 and SPL4. The MIC values to ceftriax-
one for 10 mutants derived from SPL4 were found to be 0.25 to 0.5
g/ml. Similar results were obtained for most of the mutants de-
rived from SPN284 (Table 2), but a single mutant was found to
have an MIC to ceftriaxone of 1.0g/ml. Because of the unusually
high MIC to ceftriaxone, this mutant, designated SPN284 3-1, and
a mutant derived from SPL4 with an MIC to ceftriaxone of 0.5
g/ml and designated SPL4 3-4 were retained for further charac-
terization. DNA isolated from SPN284 3-1 and from SPL4 3-4 was
used to transform the mosaic penA strain 3502 to resistance to 4.5
g/ml of cefpodoxime as described elsewhere (20, 21). Resistant
transformants appeared at a frequency of 2 103 transformants/
donor CFU. Three transformants obtained with SPN284 3-1 DNA
and three obtained with SPL4 3-4 DNA exhibited MICs identical
to those of the donor strains (Table 1). No detectible level of re-
sistance could be transformed into 28Bl, which lacks the genetic
background of 3502 (Table 1). To determine the mutation re-
sponsible for increased resistance in SPN284 3-1, DNA from the
three transformants was purified and subjected to genomic se-
quencing at the Broad Institute from modified Illumina (Illumina,
Inc., San Diego, CA) libraries (22) using either an Illumina HiSeq
2000 or Gallx instrument. Sequence alignments and analysis were
carried out with BWA version 0.5.9-r16 9 (23), SAMtools (24),
Galaxy (25–27), and SeaView version 4.2.6 (28, 29). In each trans-
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formant, a point mutation that resulted in G¡A at position 1444
was found in penA. This mutation caused the substitution G483S.
Direct sequencing of the amplified penA gene of SPN284 3-1 con-
firmed the presence of this mutation (Fig. 1A). To directly dem-
onstrate that this mutation resulted in increased resistance in
SPN284 3-1, the penA gene was amplified with specific primers
(Table 3) by PCR, and the amplified DNA was used to transform
3502 to resistance to 4.5 g/ml of cefpodoxime. The transfor-
mants, obtained at a frequency of 5 103 transformants/recip-
ient CFU, were phenotypically indistinguishable from SPN284
3-1 and the initial transformants constructed with native genomic
DNA.
A similar approach was used to characterize the mutation in
SPL4 3-4. Transformants from the cross SPL4 3-4  3502 were
selected for resistance to 3.4 g/ml of cefpodoxime. The MIC of
four transformants was found to be identical to that of the donor
strain. DNA was extracted and subjected to genome sequencing
and the data to partial analysis in the Centers for Disease Control
and Prevention (CDC) Genomics Sequencing Laboratory. The
results showed an identical 2-bp insertion in the pilQ gene of each
of the transformants (Fig. 1B). Similar to the previous experiment,
the pilQ gene was amplified (Table 3) from the DNAs of both SPL4
3-4 and 3502L3-1. Amplified DNA was used to transform 3502 as
described above. The pilQ genes from three transformants from
the SPL4 3-4 donor and two transformants from the 3502L3-1
donor, all selected on 3.4 g/ml of cefpodoxime, were sequenced.
In all cases, the same 2-bp insertion was present. All of the 3502
transformants derived from SPL4 3-4 and 3502L3-1 donors and a
Pil 3502 recipient were phenotypically Pil, not competent, and
did not revert to Pil at a detectible frequency regardless of the
source of the DNA.
The results show that it was possible to isolate in vitro a muta-
tion in the penA gene of N. gonorrhoeae that caused elevated resis-
tance to at least three different cephalosporins. This previously
unrecognized mutation in SPN284 3-1 gave a phenotype similar
to those of two strains isolated from clinical sources and was lo-
cated in the same region as mutations found in H041 and F89 (5,
6, 30). Additionally, mutations in genes other than penA can in-
crease MICs to cephalosporins, as demonstrated by the insertion
FIG 1 (A) The G¡S substitution at position 483 and the flanking amino acid
sequence for the protein coded for by the penA gene of SPN284 3-1. The
coordinate system used is from reference 20. (B) The 2-bp insertion in the
sequence of the pilQ gene of SPL4 3-4 with immediate flanking nucleotide
sequence. The alignment was with N. gonorrhoeae pilQ* (accession no.
U40596). The highlighted nucleotides denote the termination codon created
by the insertion.
TABLE 1 Properties of the strains used in this study
Strain
(references) Source
MIC (g/ml)a Genotype
Pen Cro Cfx Cpd Ery/Txb penA ponAc
SPN275 GISPd isolate 8.0 0.008 0.015 0.06 R Insertion Leu-Pro
SPN280 GISP isolate 8.0 0.015 0.03 0.03 R Insertion Leu-Pro
SPN284 GISP isolate 4.0 0.06 0.25 2.0 R Mosaic Leu-Pro
SPL4 GISP isolate 8.0 0.03 0.25 2.0 R Mosaic Leu-Pro
3502 Reference isolate 4.0 0.03 0.25 1.0 R Mosaic Leu-Pro
28Bl (20, 21) DGI isolate (CDC, 1974) 0.015 0.008 0.015 0.06 S WTe WT
SPN284 3-1 Spontaneous mutant of SPN284 16.0 1.0 1.0 8.0 R Mosaic Leu-Pro
SPL4 3-4 Spontaneous mutant of SPL4 32.0 0.5 1.0 8.0 R Mosaic Leu-Pro
3502T1 Transformant SPN284 3-1 3502 32.0 1.0 1.0 8.0 R Mosaic Leu-Pro
3502T2 Transformant SPN284 3-1 3502 32.0 1.0 1.0 8.0 R Mosaic Leu-Pro
3502T4 Transformant SPN284 3-1 3502 32.0 1.0 1.0 8.0 R Mosaic Leu-Pro
3502L3-1 Transformant SPL4 3-4 3502 32.0 0.5 1.0 8.0 R Mosaic Leu-Pro
3502L3-2 Transformant SPL4 3-4 3502 32.0 0.5 1.0 8.0 R Mosaic Leu-Pro
3502L3-3 Transformant SPL4 3-4 3502 32.0 0.5 1.0 8.0 R Mosaic Leu-Pro
3502L3-4 Transformant SPL4 3-4 3502 32.0 0.5 1.0 8.0 R Mosaic Leu-Pro
a Pen, penicillin; Cro, ceftriaxone; Cfx, cefixime; Cpd, cefpodoxime.
b Resistance to 600 g/ml Triton X-100 and 1.2 g/ml of erythromycin (Ery/Tx) was used to determine the MtrR phenotype (13). R, resistant; S, susceptible.
c The genes sequenced show the Leu-Pro substitution at amino acids associated with -lactam resistance (29).
d GISP, Gonococcal Isolate Surveillance Project.
e WT, wild type.
TABLE 2 MICs of mutants selected on cefpodoxime gradient plates
Cpd
concn
(g/ml)a Strain
No. of
isolates
tested
MIC (g/ml)b
Pen Tet Cro Cfx Cpd
4.0 SPL4 5 32.0–64.0 4.0–8.0 0.25–0.5 0.5 8.0
SPN284 4 16.0 4.0 0.25–0.5 0.5 8.0
6.0 SPL4 8 32.0–64.0 4.0–8.0 0.25–0.5 0.5–1.0 8.0
SPN284 3 32.0 4.0 0.25–0.5 1.0 8.0
a Concentration of cefpodoxime (Cpd) in the gradient plate substratum used for in
vitro selection of mutants with elevated MICs to cefpodoxime.
b Pen, penicillin; Tet, tetracycline; Cro, ceftriaxone; Cfx, cefixime.
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mutation in pilQ present in SPL4 3-4. Alteration of pilQ was pre-
viously shown to increase resistance to penicillin by alteration of
the permeability of the outer membrane (31, 32). These results
demonstrate that this mutation in pilQ had a similar effect on
cephalosporin resistance and increased the MIC to ceftriaxone
almost 10-fold. Because mutations in pilQ commonly result in a
Pil phenotype, it is not evident that such mutations will be
of consequence, as piliation is required for pathogenesis (33,
34).Since mutations in pilQ can result in complex phenotypes
(35), it may be possible to isolate mutations in pilQ that allow for
both pathogenesis and for increased cephalosporin resistance.
Finally, it is apparent that caution must be used in selecting
alternative cephalosporins and possibly other -lactam antibiot-
ics for treatment of gonococcal infections. While mutants resis-
tant to slightly elevated concentrations of ceftriaxone or cefixime
were difficult to isolate (data not shown), it proved relatively easy
to select mutants resistant to moderate concentrations of cefpo-
doxime that also showed significantly increased resistance to both
of the other antibiotics, suggesting that the use of cefpodoxime
could adversely affect the value of the other cephalosporins.
Nucleotide sequence accession numbers. The complete se-
quences of the penA genes of SPN284 and SPN284 3-1 and the pilQ
gene of SPL4 3-4 have been deposited in GenBank under accession
no. KM403400, KM403401, and KM452733, respectively.
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